Ann: Investor Presentation, page-296

I actually do not mind those guys chiming in as it opens the discussion. Its a positive imo.

Important things that many of CYP followers here have learned this week, but not limited to:

1. No evidence that any other company has valid claims on CYPs patents.

2. There are already measures in place to significantly reduce the risk of cancer mutations in the expansion process of our IPSCs and differentiation process of our IPSC derived MSC. In fact, IPSC MSCs appear to pose less risk compared to bone marrow derived technologies with the headache of batch to batch variability and more.

I'm feeling more bullish than ever as a result of these conversations that service as new information to some and reminders to others.